$ARFXF News

Last published 4y ago

4y agoARFXFPROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIAGlobeNewswireTORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as t
4y agoARFXFProMIS Neurosciences Announces Debt Amendment and ConversionGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics ta
4y agoARFXFProMIS Neurosciences Announces Authorization of Series 1 Preferred SharesGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics ta
4y agoARFXFProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing ApplicationGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics t
4y agoARFXFProMIS Neurosciences presents at the 2022 Neuro4D International ConferenceGlobeNewswireTORONTO, Ontario and CAMBRIDGE, MA, May 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligome
4y agoARFXFCORRECTION: ProMIS Neurosciences Announces First Quarter 2022 ResultsGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no other changes to the release. Please find full correc
4y agoARFXFProMIS Holds Annual and Special Meeting of Shareholders All Resolutions ApprovedGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Corporation"), is pleased to announce the Annual and Special Meeting of Shareholders (the "Meeting") of
4y agoARFXFProMIS Neurosciences Announces First Quarter 2022 ResultsGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics ta
4y agoARFXFIndependent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of ShareholdersGlobeNewswireTORONTO, Ontario, May 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company") is pleased to announce that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and G
4y agoARFXFProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)GlobeNewswireTORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as t
4y agoARFXFProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical OfficerGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFArgus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)PR NewswireNEW YORK , April 18, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN)
4y agoARFXFProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual MeetingGlobeNewswireTORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligo
4y agoARFXFProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of ShareholdersGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Corporation"), is pleased to announce it has mailed the Notice of Notice-and-Access (the "N&A Notice")
4y agoARFXFProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development SummitGlobeNewswireTORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic olig
4y agoARFXFProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic
4y agoARFXFProMIS Neurosciences Announces Fiscal Year 2021 ResultsGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics
4y agoARFXFProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) and Related Neurological DisordersGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic ol
4y agoARFXFProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's diseaseGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory BoardGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory BoardGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory BoardGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer's TreatmentGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual ConferenceGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as
4y agoARFXFProMIS Neurosciences Issues Chairman's MemorandumGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated
4y agoARFXFProMIS Neurosciences Shareholders Approve Special ResolutionGlobeNewswireTORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) (the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers impli
4y agoARFXFA Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share ConsolidationGlobeNewswireFor any questions, please contact ProMIS' proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO, Ontario and CAMBRIDGE, Mass. , Nov. 17, 202
5y agoARFXFProMIS Neurosciences Announces Third Quarter 2021 ResultsGlobeNewswireTORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS or the Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic olig
5y agoAAZZF ABIO ACOGF ACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
5y agoARFXFGlass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special MeetingGlobeNewswireFor any questions, please contact ProMIS' proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWI
5y agoARFXFProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of DirectorsGlobeNewswireTORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implica
5y agoARFXFProMIS Neurosciences Announces Update to Senior Management TeamGlobeNewswireTORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implica
5y agoARFXFProMIS Neurosciences Files Special Meeting Proxy MaterialGlobeNewswireFor any questions, please contact ProMIS' proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO and CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE)
5y agoARFXFProMIS Neurosciences Announces Special Shareholder MeetingGlobeNewswireTORONTO and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) (the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers impli
5y agoARFXFProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021GlobeNewswireTORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the d
5y agoARFXFProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment ConferenceGlobeNewswireTORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the d
5y agoARFXFProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of DirectorsGlobeNewswireTORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implic
5y agoARFXFProMIS Neurosciences Announces Second Quarter 2021 ResultsGlobeNewswireTORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS or the Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic olig
5y agoARFXFProMIS Neurosciences Issues Chairman's MemorandumGlobeNewswireTORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
5y agoARFXFProMIS Neurosciences to Present at 2021 Alzheimer's Association International ConferenceGlobeNewswireTORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
5y agoARFXFProMIS Neurosciences Obtains Receipt for Final Base Shelf ProspectusGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Pro
5y agoARFXFProMIS Neurosciences Announces Results of Annual Meeting of ShareholdersGlobeNewswireTORONTO and CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
5y agoARFXFProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer's diseaseGlobeNewswireTORONTO and CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
5y agoARFXFProMIS Neurosciences Files Preliminary Short Form Base Shelf ProspectusGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- ProM
5y agoARFXFProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics OfficerGlobeNewswireTORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the de
5y agoARFXFProMIS Neurosciences initiates commercialization of COVID-19 serology assayGlobeNewswireTORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicat
5y agoARFXFProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line developmentGlobeNewswireTORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicat
5y agoARFXF IMABProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of DirectorsGlobeNewswireTORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicat
5y agoARFXF IMABProMIS Neurosciences Announces First Quarter 2021 ResultsGlobeNewswireTORONTO and CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF) ("ProMIS or the Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligo
5y agoARFXFProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory BoardGlobeNewswireTORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicat